Expert Forum on Bladder Cancer: Recent FDA approvals


“There's unquestionably a real signal for…agents that are well tolerated that can be given for a long period of time,” says Sam S. Chang, MD, MBA.

In this video Sam S. Chang, MD, MBA, and Christopher B. Anderson, MD, MPH,discuss the recent FDA approvals of pembrolizumab (Keytruda) and nivolumab (Opdivo) and what they continue to learn from immunotherapy treatments. This discussion is part of a larger forum on bladder cancer with Chad R. Ritch, MD, MBA, FACS. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.

Related Videos
3d rendered illustration of bladder cancer | Image Credit: © SciePro -
Dr. Joshua Meeks in an interview with Urology Times
Alexander I. Sankin, MD, and Ahmed A. Aboumohamed, MD, answer questions during a video interview
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Daniel P. Petrylak, MD, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.